Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 4 minute read Pharma Industry News Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment. byPallavi MadhirajuMarch 24, 2025